Fenwick Represents CareDX in Divestiture of Lab Products Business to EuroBio Scientific

Fenwick is representing CareDx, Inc. (Nasdaq: CDNA), a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, in the pending divestiture of its Lab Products business to EuroBio Scientific.

The divestiture is intended to simplify CareDx’s operating model and support disciplined capital redeployment toward opportunities aligned with its Precision Medicine Testing Services model. More information can be obtained from CareDx’s announcement.

The Fenwick transaction team includes corporate partners Doug Cogen, Lynda Twomey and Eric Shedlosky and associates Jordan Beals, Max Krinsky and Guy Rotstein; technology transactions partner Jake Handy, associates Pinar Bailey and Kiyan Savar and advisor Sandra Weustink; executive compensation and employee benefits partner Liz Gartland and associate Christophe Delrieu; privacy and cybersecurity partner Ana Razmazma, counsel Sari Ratican and associates Jason Raylesberg and Alyona Eidinger; trade and national security partner Robert Slack and associates Brooklynn Moore and Jake Medvitz; antitrust and competition partner Steve Albertson and counsel Meredith Mommers; and tax partner William Skinner and associate Kris Hatch.